Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4068 Target Snapshot

Chymase · SINGLE PROTEIN · Homo sapiens

794Compounds
92Assays
2Approved Drugs
758.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Chymase shows clinical signal disease relevance led by diabetic nephropathy. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P23946. Start with diabetic nephropathy, then reuse UniProt P23946 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetic nephropathy, then reuse UniProt P23946 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
diabetic nephropathy

Chymase shows clinical signal disease relevance led by diabetic nephropathy. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with diabetic nephropathy because it currently carries clinical signal support. Linked drugs include FULACIMSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Chymase as ChEMBL target CHEMBL4068, mapped to UniProt P23946. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Chymase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4068
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P23946
Chymase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Chymase is the right protein anchor across sources, using UniProt P23946 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetic nephropathy is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelChymase
UniProt AccessionP23946
Component TypeProtein
Sequence Length247 aa

Chymase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Chymase, mapped to UniProt P23946. Sequence length is 247 aa.

Mapped IDP23946
Review nameChymase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Chymase shows clinical signal disease relevance led by diabetic nephropathy. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
diabetic nephropathy
1 linked drug · 1 direct · 1 efficacy
Linked drugFULACIMSTAT
Clinical signal Phase II
heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugFULACIMSTAT
Clinical signal Phase II
myocardial infarction
1 linked drug · 1 direct · 1 efficacy
Linked drugFULACIMSTAT
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with diabetic nephropathy because it currently carries clinical signal support. Linked drugs include FULACIMSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetic nephropathy
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50621.0
KI135.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4592765 9.66 Ki 0.22 Preclinical
CHEMBL3640120 9.52 IC50 0.3 Preclinical
CHEMBL3640116 9.4 IC50 0.4 Preclinical
CHEMBL1631751 9.34 IC50 0.46 Preclinical
CHEMBL3640115 9.15 IC50 0.7 Preclinical
CHEMBL3640118 9.15 IC50 0.7 Preclinical
CHEMBL44950 9.07 IC50 0.85 Preclinical
CHEMBL3640105 9.05 IC50 0.9 Preclinical
CHEMBL26285 8.95 Ki 1.12 Preclinical
CHEMBL353816 8.89 Ki 1.3 Preclinical
Distribution

pChEMBL Value Distribution

36
5.0
66
5.5
108
6.0
118
6.5
127
7.0
107
7.5
55
8.0
25
8.5
7
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

TELAPREVIR
CHEMBL231813
Approved 2011
BOCEPREVIR
CHEMBL218394
Approved 2011
Assay Landscape

Assay Landscape

92
Total Assays
640
Tested Compounds
2
Assay Types
Binding — 88 assays, 640 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 79 474 6.8
cell-based format 7 165 7.0
assay format 1 0
cell-free format 1 1 6.7
ADME — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 0
single protein format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine